阿帕替尼治疗晚期肺癌的疗效及疗效预测因子分析

发布时间：2018-05-13 11:51

  本文选题：阿帕 + 甲磺酸　； 参考：《实用医学杂志》2017年22期

【摘要】：正晚期肺癌的预后差,在靶向治疗及化疗失败后并没有很有效的治疗选择~([1-2])。甲磺酸阿帕替尼是我国自主开发的一种针对VEGFR2的小分子靶向药物,在胃癌及乳腺癌中已见到明显疗效~([3-4])。在非小细胞肺癌中,国内也有报道,显示了一定的疗效~([5])。本研究收集了本院2014年12月到2017年1月间经甲磺酸阿帕替尼治疗的晚期肺癌患者31例,观察了其在不同肺癌类型中的近期疗效、不良反应,同时
[Abstract]:The prognosis of advanced lung cancer is poor and there is no effective treatment choice ([1-2]) after the failure of targeted therapy and chemotherapy. Apatinib mesylate is a small molecular targeted drug for VEGFR2 in China. It has been shown to be effective in gastric cancer and breast cancer ([3-4]). In non-small cell lung cancer (NSCLC), there are also reports in China, showing a certain curative effect ([5]). This study collected 31 patients with advanced lung cancer treated with Apatinib mesylate from December 2014 to January 2017, and observed their short-term efficacy, adverse reactions and adverse reactions in different types of lung cancer.
【作者单位】： 江苏省连云港市第二人民医院肿瘤化疗科;
【分类号】：R734.2
，

本文编号：1883024